Table 1.
Clinicopathologic Features and Univariate Analysis by the Presence or Absence of Metastatic Non-SLN in Our Chinese Patients With Breast Cancer.a
| Characteristics | Non-SLN Metastasis; Present, n = 105 | Non-SLN Metastasis; Absent, n = 131 | Significance, P Value |
|---|---|---|---|
| Age, years, n (%) | .67 | ||
| ≤50 | 67 (63.8%) | 80 (61.1%) | |
| >50 | 38 (36.2%) | 51 (38.9%) | |
| Axillary ultrasonography, n (%) | .087 | ||
| Low suspicion of LN metastasis | 62 (59.0%) | 85 (64.9%) | |
| High suspicion of LN metastasis | 21 (20.0%) | 13 (9.9%) | |
| Not done | 22 (21.0%) | 33 (25.2%) | |
| Primary tumor size, n (%) | .0015 | ||
| T1 | 42 (40.0%) | 73 (55.7%) | |
| T2 | 51 (48.6%) | 56 (42.7%) | |
| T3 | 12 (11.4%) | 2 (1.5%) | |
| Operation, n (%) | .24 | ||
| Conservative | 10 (9.5%) | 19 (14.5%) | |
| Mastectomy | 95 (90.5%) | 112 (85.5%) | |
| Location of primary tumor, n (%) | .78 | ||
| Upper outer | 33 (31.4%) | 41 (31.3%) | |
| Upper inner | 12 (11.4%) | 18 (13.7%) | |
| Lower outer | 17 (16.2%) | 14 (10.7%) | |
| Lower inner | 7 (6.7%) | 10 (7.6%) | |
| Central or 2 quadrant | 36 (34.4%) | 48 (36.6%) | |
| Multifocality of primary tumor, n (%) | .65 | ||
| Yes | 8 (7.6%) | 8 (6.1%) | |
| No | 97 (92.4%) | 123 (93.9%) | |
| Histological type of primary tumor, n (%) | .64 | ||
| Invasive ductal carcinoma | 94 (89.5%) | 117 (89.3%) | |
| Invasive lobular carcinoma | 6 (5.7%) | 5 (3.8%) | |
| Other type | 5 (4.8%) | 9 (6.9%) | |
| Histological grade of primary tumor, n (%) | .05 | ||
| Ductal, I | 2 (1.9%) | 8 (6.1%) | |
| Ductal, II | 41 (39.0%) | 64 (48.9%) | |
| Ductal, III | 49 (46.7%) | 44 (33.6%) | |
| Unclear | 13 (12.4%) | 15 (11.5%) | |
| Lymphovascular invasion, n (%) | <.001 | ||
| Present | 50 (47.6%) | 34 (26.0%) | |
| Absent | 55 (52.4%) | 97 (74.0%) | |
| ER status, n (%) | .49 | ||
| Positive | 78 (77.2%) | 98 (81.0%) | |
| Negative | 23 (22.8%) | 23 (19.0%) | |
| Unclear | 4 (3.8%) | 10 (7.6%) | |
| PR status, n (%) | .46 | ||
| Positive | 75 (74.3%) | 95 (78.5%) | |
| Negative | 26 (25.7%) | 26 (21.5%) | |
| Unclear | 4 (3.8%) | 10 (7.6%) | |
| Her-2 status, n (%) | .19 | ||
| Positive | 30 (29.1%) | 30 (24.6%) | |
| Intermediate | 4 (3.9%) | 1 (0.8%) | |
| Negative | 69 (67.0%) | 92 (75.4%) | |
| Unclear | 2 (1.9%) | 8 (6.1%) | |
| Ki 67, n (%) | .35 | ||
| Low | 23 (22.1%) | 36 (27.5%) | |
| High | 81 (77.9%) | 95 (72.5%) | |
| Unclear | 1 (1.0%) | 0 | |
| Method of detection, n (%) | .25 | ||
| FS | 70 (66.7%) | 95 (72.5%) | |
| Routine H&E | 12 (11.4%) | 18 (13.7%) | |
| Serial H&E | 19 (18.1%) | 17 (13.0%) | |
| IHC | 4 (3.8%) | 1 (0.8%) | |
| Sentinel lymph node features | |||
| No of SLNs excised, n (%) | .50 | ||
| 1 | 18 (17.1%) | 16 (12.2%) | |
| 2 | 17 (16.2%) | 28 (21.4%) | |
| 3 | 19 (18.1%) | 16 (12.2%) | |
| 4 | 21 (20.0%) | 19 (14.5%) | |
| ≥5 | 30 (28.6%) | 42 (32.1%) | |
| Number of metastatic SLN, n (%) | <.001 | ||
| 1 | 50 (47.6%) | 95 (72.5%) | |
| 2 | 27 (26.0%) | 23 (17.6%) | |
| 3 | 13 (12.5%) | 12 (9.2%) | |
| ≥4 | 15 (14.3%) | 1 (0.8%) | |
| Number of nonmetastatic SLN, n (%) | .005 | ||
| 0 | 38 (36.2%) | 23 (17.6%) | |
| 1 | 17 (16.2%) | 34 (26.0%) | |
| 2 | 19 (18.1%) | 21 (16.0%) | |
| 3 | 16 (15.2%) | 18 (13.7%) | |
| ≥4 | 15 (14.3%) | 35 (26.7%) | |
| Proportion of metastatic SLN/total SLN, n (%) | .0035 | ||
| <0.5 | 35 (33.3%) | 64 (48.9%) | |
| Between 0.5 and 1 | 32 (30.5%) | 44 (33.6%) | |
| 1 | 38 (36.2%) | 23 (17.6%) | |
| Size of SLN metastasis | .30 | ||
| ITC | 2 (1.9%) | 1 (0.8%) | |
| Micrometastasis | 2 (1.9%) | 7 (5.3%) | |
| Macrometastasis | 101 (96.2%) | 123 (93.9%) | |
| Extracapsular extension | .36 | ||
| Present | 5 (4.8%) | 10 (7.6%) | |
| Absent | 100 (95.2%) | 121 (92.4%) | |
Abbreviations: ER, estrogen receptor; FS, frozen section; H&E, hematoxylin and eosin; HER-2, human epidermal growth factor receptor 2; ITC, isolated tumor cell; LN, lymph node; PR, progesterone receptor; SLN, sentinel lymph node.
a n = 236.